Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on ACAD, ANAC, AFFY and DNN Issued by the Bedford Report

ACAD, AFFY, T.DML
Free Research Reports on ACAD, ANAC, AFFY and DNN Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=999587&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 03/22/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares soared 23.91 percent on volume of over 22 million shares traded Thursday to close at $8.24 a share. The company announced that they reported positive results from a Phasse III study of their Parkinson's drug, pimavanserin, at the American Academy of Neurology Annual Meeting.

Find out more about ACADIA Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ACAD

Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) shares spiked 26.04 percent on more than three times the average daily volume Thursday to close at $4.84 a share. The company has reported positive results from a Phase II study of AN2728 in adolescents with atopic dermatitis.

Find out more about Anacor Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ANAC

Affymax, Inc. (NASDAQ: AFFY) shares rallied 17.46 percent on volume of over 20 million shares traded Thursday to close at $1.48 a share. The company recently announced plans to cut approximately 75% of its workforce (230 employees) as part of a plan to focus resources on the ongoing investigation of OMONTYS.

Find out more about Affymax including full access to the free equity report at: www.BedfordReport.com/AFFY

Denison Mines Corp. (NYSE: DNN)(TSX: DML) shares surged 9.49 percent on volume of 1.30 million shares traded Thursday to close at $1.50 a share. The company has recently announced that it has identified a new area of interest at Wheeler River.

Find out more about Denison Mines including full access to the free equity report at: www.BedfordReport.com/DNN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact